Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Accumulated Expenses (2022 - 2023)

Day One Biopharmaceuticals (DAWN) has disclosed Other Accumulated Expenses for 2 consecutive years, with $1.0 million as the latest value for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses rose 481.56% year-over-year to $1.0 million; the TTM value through Dec 2023 reached $1.0 million, up 481.56%, while the annual FY2023 figure was $1.0 million, 481.56% up from the prior year.
  • Other Accumulated Expenses was $1.0 million for Q4 2023 at Day One Biopharmaceuticals, up from $179000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.0 million in Q4 2023, with the low at $179000.0 in Q4 2022.